Sunshine Biopharma (SBFM)
Market Price (2/2/2026): $1.21 | Market Cap: $5.5 MilSector: Health Care | Industry: Pharmaceuticals
Sunshine Biopharma (SBFM)
Market Price (2/2/2026): $1.21Market Cap: $5.5 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -152% | Weak multi-year price returns2Y Excs Rtn is -142%, 3Y Excs Rtn is -173% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -22% | |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 1516% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -112% | ||
| Key risksSBFM key risks include [1] a history of unprofitability and reliance on potentially dilutive financing, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -152% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -142%, 3Y Excs Rtn is -173% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -4.9 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -13% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -22% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 1516% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -112% |
| Key risksSBFM key risks include [1] a history of unprofitability and reliance on potentially dilutive financing, Show more. |
Stock Movement Drivers
Fundamental Drivers
The -31.1% change in SBFM stock from 10/31/2025 to 2/1/2026 was primarily driven by a -95.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.77 | 1.22 | -31.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 36 | 37 | 2.7% |
| P/S Multiple | 0.0 | 0.1 | 1260.1% |
| Shares Outstanding (Mil) | 0 | 5 | -95.1% |
| Cumulative Contribution | -31.1% |
Market Drivers
10/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| SBFM | -31.1% | |
| Market (SPY) | 1.5% | 30.4% |
| Sector (XLV) | 7.3% | 24.5% |
Fundamental Drivers
The -15.3% change in SBFM stock from 7/31/2025 to 2/1/2026 was primarily driven by a -40.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.44 | 1.22 | -15.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 36 | 37 | 3.0% |
| P/S Multiple | 0.1 | 0.1 | 38.6% |
| Shares Outstanding (Mil) | 3 | 5 | -40.7% |
| Cumulative Contribution | -15.3% |
Market Drivers
7/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| SBFM | -15.3% | |
| Market (SPY) | 9.8% | 19.1% |
| Sector (XLV) | 19.2% | 20.4% |
Fundamental Drivers
The -57.2% change in SBFM stock from 1/31/2025 to 2/1/2026 was primarily driven by a -72.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.85 | 1.22 | -57.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 33 | 37 | 13.2% |
| P/S Multiple | 0.1 | 0.1 | 35.7% |
| Shares Outstanding (Mil) | 1 | 5 | -72.2% |
| Cumulative Contribution | -57.2% |
Market Drivers
1/31/2025 to 2/1/2026| Return | Correlation | |
|---|---|---|
| SBFM | -57.2% | |
| Market (SPY) | 16.0% | 39.7% |
| Sector (XLV) | 6.8% | 26.8% |
Fundamental Drivers
The -100.0% change in SBFM stock from 1/31/2023 to 2/1/2026 was primarily driven by a -99.8% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312023 | 2012026 | Change |
|---|---|---|---|
| Stock Price ($) | 2460.00 | 1.22 | -100.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 37 | 7503.5% |
| P/S Multiple | 47.3 | 0.1 | -99.7% |
| Shares Outstanding (Mil) | 0 | 5 | -99.8% |
| Cumulative Contribution | -100.0% |
Market Drivers
1/31/2023 to 2/1/2026| Return | Correlation | |
|---|---|---|
| SBFM | -100.0% | |
| Market (SPY) | 76.6% | 15.3% |
| Sector (XLV) | 21.4% | 8.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SBFM Return | 0% | 42567% | -58% | -99% | -59% | 1% | -59% |
| Peers Return | 433948% | -72% | -35% | -47% | -48% | -1% | 20960% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 2% | 86% |
Monthly Win Rates [3] | |||||||
| SBFM Win Rate | 0% | 42% | 17% | 33% | 33% | 100% | |
| Peers Win Rate | 25% | 28% | 40% | 33% | 30% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 100% | |
Max Drawdowns [4] | |||||||
| SBFM Max Drawdown | 0% | 0% | -63% | -100% | -59% | -2% | |
| Peers Max Drawdown | -43% | -77% | -70% | -64% | -55% | -12% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: APRE, ENSC, SCYX, CING, BRTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/30/2026 (YTD)
How Low Can It Go
| Event | SBFM | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -97.5% | -25.4% |
| % Gain to Breakeven | 3954.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -80.0% | -33.9% |
| % Gain to Breakeven | 400.0% | 51.3% |
| Time to Breakeven | 73 days | 148 days |
Compare to APRE, ENSC, SCYX, CING, BRTX
In The Past
Sunshine Biopharma's stock fell -97.5% during the 2022 Inflation Shock from a high on 4/7/2022. A -97.5% loss requires a 3954.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Sunshine Biopharma (SBFM)
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
AI Analysis | Feedback
1. Like a very early-stage Merck or Pfizer, but entirely focused on developing new cancer drugs from the ground up.
2. Similar to a startup version of a biotech giant such as Amgen or Gilead Sciences, concentrating on early-stage drug discovery for cancer and viral diseases.
AI Analysis | Feedback
- Adva-27a: An anti-cancer drug candidate designed to specifically target and destroy multidrug resistant cancer cells.
- SBFM-PL1: A new generation of anti-cancer drug candidates currently in early development.
- mRNA-based COVID-19 Drug Candidates: Therapeutic mRNA molecules designed to inhibit the replication of the SARS-CoV-2 virus.
- Small Molecule COVID-19 Drug Candidates: Small molecule compounds aimed at inhibiting the replication of the SARS-CoV-2 virus.
AI Analysis | Feedback
Sunshine Biopharma (SBFM) - Major Customers
Sunshine Biopharma (SBFM) primarily sells its products and services to individuals through its wholly-owned retail pharmacy chain, "Pharmacies Universelles," located in Quebec, Canada. The company operates its pharmaceutical sales division through these pharmacies, directly serving the public.
The categories of individual customers served by Sunshine Biopharma's retail pharmacies include:
- Patients with Chronic Conditions: Individuals requiring regular prescription refills for ongoing health management, such as those with diabetes, hypertension, or other long-term illnesses.
- Patients with Acute Conditions: Individuals seeking medications for short-term illnesses, injuries, or post-operative recovery, including prescriptions for antibiotics, pain management, or temporary health issues.
- General Consumers of Over-the-Counter (OTC) Products and Pharmacy Services: Customers purchasing non-prescription health products (e.g., vitamins, cold and flu remedies, first-aid supplies) and utilizing pharmacy services like vaccinations or health consultations.
AI Analysis | Feedback
nullAI Analysis | Feedback
Dr. Steve N. Slilaty, President, Chairman of the Board and Chief Executive Officer
Dr. Slilaty received his Ph.D. in Molecular Biology & Biochemistry from the University of Arizona and his Bachelor of Science in Genetics and Biochemistry from Cornell University. He has served as CEO of Sunshine Biopharma since October 2009. He is an accomplished scientist, credited with discovering a new class of enzymes and developing the TrueBlue Cloning System, a key technology for the Human Genome Project. Dr. Slilaty founded three biotechnology companies and successfully took one public, Genomics One Corporation, which achieved a $1 billion market capitalization and is now known as Alert BC Corporation. He also founded Quantum Biotechnologies Inc. (later Qbiogene Inc.) in 1991, which grew to over $60 million in annual sales and is currently a member of the MP Biomedicals family of companies. His third venture was Advanomics Corporation, a privately held company he co-founded with Camille Sebaaly, focused on cancer drug research and development, where he has been President and Chief Scientific Officer since February 2002.
Camille Sebaaly, Chief Financial Officer, Principal Accounting Officer and Secretary
Mr. Sebaaly has been with Sunshine Biopharma since its inception in 2009. He co-founded Advanomics Corporation with Dr. Steve N. Slilaty. He previously served as a director of Sunshine Biopharma but resigned from that role in November 2021, continuing as CFO. He has made insider purchases of Sunshine Biopharma shares.
Dr. Abderrazzak Merzouki, Chief Operating Officer and Director
Dr. Merzouki has served as Chief Operating Officer and a Director of Sunshine Biopharma since 2016.
Michel Roy, Chief Commercial Officer
Mr. Roy was appointed Chief Commercial Officer of Sunshine Biopharma effective January 15, 2025. He brings over 20 years of experience in the pharmaceutical industry, having held various leadership positions at major international pharmaceutical companies. From 2020 to 2024, he founded and led the Canadian operations of Shilpa Medicare Ltd. Prior to that, from 2014 to 2020, he served as Vice President, Business Development and Sales for Intas Pharmaceuticals Ltd. Mr. Roy also worked as a consultant for several international Contract Research Organization (CRO) companies. He holds an Executive Master of Business Administration (EMBA) from John Molson School of Business and a Master of Science (M.Sc.) from Université de Montréal.
Robert Ferreira, President of Sunshine Bio Investments Inc.
Robert Ferreira serves as the President of Sunshine Bio Investments Inc.
AI Analysis | Feedback
Sunshine Biopharma (SBFM) faces several significant risks to its business operations. The most prominent challenges include its ongoing unprofitability and reliance on external funding, the inherent uncertainties and regulatory hurdles in its drug development pipeline, and the competitive and price-sensitive nature of its generic pharmaceutical business.- Unprofitability and Reliance on External Funding: Sunshine Biopharma has a history of unprofitability, with reported consecutive quarterly losses and a pattern of burning cash to fund its research and development initiatives and Canadian generic drug operations. While the company maintains a low debt-to-equity ratio, it frequently resorts to equity financing through stock sales to raise capital. This approach can lead to significant shareholder dilution. The ability to achieve sustained profitability, particularly from its drug development efforts, remains highly uncertain and dependent on future success.
- High-Risk Drug Development and Regulatory Approval Process: As a biopharmaceutical company, Sunshine Biopharma's long-term growth and success are heavily dependent on the successful development and commercialization of its pipeline drug candidates, such as K1.1 mRNA for liver cancer and SBFM-PL4 for coronavirus infections. This process is inherently risky, lengthy, and expensive, with no guarantee of favorable clinical trial results or regulatory approval. The company has even paused the development of one candidate, Adva-27a, due to unfavorable in vitro results. Failure to obtain necessary regulatory approvals would materially harm the business and limit its ability to generate significant product revenues.
- Challenges within the Generic Pharmaceutical Business: Sunshine Biopharma currently generates most of its revenue through the sale of generic pharmaceutical products in Canada, following its acquisition of Nora Pharma. However, the generic pharmaceutical market is characterized by lower profit margins compared to innovative medicines. The business is also exposed to increased volatility due to global supply chain issues and intense pricing pressures, particularly from government-led negotiations in Canada. These factors can negatively impact the company's net sales and overall financial performance.
AI Analysis | Feedback
null
AI Analysis | Feedback
Sunshine Biopharma (SBFM) operates in various therapeutic areas, with its main products and services targeting oncology, antiviral treatments, and generic pharmaceuticals. The addressable markets for these offerings vary by product and region.
Proprietary Drug Pipeline
- Adva-27a (Pancreatic Cancer Treatment): Adva-27a is a small-molecule anticancer compound designed to target aggressive cancers, including pancreatic cancer and multi-drug resistant breast cancer. The global pancreatic cancer treatment market was valued at approximately $2.47 billion in 2022 and is projected to reach $7.88 billion by 2030, with a compound annual growth rate (CAGR) of 15.6%. Broader, the global cancer therapeutics market was estimated at USD 194.67 billion in 2024 and is projected to grow to USD 469.38 billion by 2034, with a CAGR of 9.20% from 2025 to 2034.
- K1.1 mRNA (Liver Cancer): K1.1 mRNA is a lipid nanoparticle being developed for liver cancer. The global mRNA therapeutics market, which encompasses this technology, was valued at USD 8.05 billion in 2024 and is projected to reach USD 36.25 billion by 2032, growing at a CAGR of 16.70% from 2025 to 2032. Another estimate indicates the global mRNA therapeutics market was valued at USD 11.75 billion in 2023 and is projected to reach USD 31.30 billion by 2030, with a CAGR of 17.05% from 2024 to 2030. North America holds a dominant position in the mRNA therapeutics market.
- SBFM-PL4 (SARS Coronavirus Infections): SBFM-PL4 is a protease inhibitor in development for the treatment of SARS coronavirus infections. Sunshine Biopharma estimates the combined addressable market for its three novel drug candidates (Adva-27a, K1.1 mRNA, and SBFM-PL4) to be $32 billion. Specific individual market sizing for SBFM-PL4 was not identified.
Generic Pharmaceuticals
- Canadian Generic Drug Market: Sunshine Biopharma offers a range of generic pharmaceutical products for various therapeutic areas. The Canadian generic drug market reached an estimated $8.9 billion in sales in 2022 and is forecasted to grow to $14.8 billion by 2028, exhibiting a CAGR of 8.5% from 2023 to 2028.
Other Products and Services
- Nonprescription Over-The-Counter Products and Research & Development Services: Sunshine Biopharma also provides nonprescription over-the-counter products, including amino acid capsules, and offers contract research and development services to other pharmaceutical companies. Specific addressable market sizes for these particular categories were not found.
AI Analysis | Feedback
Sunshine Biopharma (SBFM) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives: * Expansion of Generic Drug Portfolio: Sunshine Biopharma's wholly-owned subsidiary, Nora Pharma Inc., is a significant revenue generator. The company plans to continue expanding its portfolio of generic prescription drugs in Canada, with 72 generic drugs currently on the market and more than 12 additional drugs planned for launch in the remainder of 2025. This growth in its generic pharmaceutical business is expected to contribute to profitability by fiscal year 2025. * Launch and Commercialization of Biosimilars: The company has strategically moved into the biosimilar market with the launch of NIOPEG®, a biosimilar to Neulasta. This positions Sunshine Biopharma in a competitive, higher-margin segment of the pharmaceutical industry, offering a new avenue for revenue growth. * Advancement of Proprietary Drug Pipeline: Sunshine Biopharma is actively developing a proprietary therapeutic drug pipeline that addresses large markets with unmet needs. Key candidates include K1.1 mRNA for liver cancer and an SBFM-PL4 PLpro inhibitor for SARS Coronavirus infections (including Long-Covid). While these are in early development stages, with Phase 1 clinical trials for K1.1 mRNA and the PLpro inhibitor programs expected in the second half of 2024, their successful progression and eventual commercialization could represent substantial future revenue streams. * Increased Market Penetration in Canada's Generic Pharmaceutical Market: Beyond simply adding new products, Nora Pharma aims to strengthen its foothold in Canada's growing generic drug market. This involves expanded sales efforts and strategic support to increase market penetration for its existing and newly launched generic offerings.AI Analysis | Feedback
Share Issuance
- In February 2022, Sunshine Biopharma completed a public offering of 1,882,353 units, each consisting of one share of common stock and two warrants, at a price of $4.25 per unit, generating approximately $8.0 million.
- The company recorded $3.61 million in cash generated from financing activities during the second quarter of 2025.
Outbound Investments
- On October 20, 2022, Sunshine Biopharma acquired Nora Pharma Inc., a Canadian generic pharmaceuticals company, for C$30 million.
- In October 2025, the company invested $5 million in a digital treasury asset to bolster its balance sheet.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Sunshine Biopharma Earnings Notes | 12/16/2025 | |
| How Low Can Sunshine Biopharma Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 0.97 |
| Mkt Cap | 0.0 |
| Rev LTM | 0 |
| Op Inc LTM | -14 |
| FCF LTM | -12 |
| FCF 3Y Avg | -10 |
| CFO LTM | -12 |
| CFO 3Y Avg | -9 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 1.7% |
| Rev Chg 3Y Avg | 1,001.2% |
| Rev Chg Q | -49.4% |
| QoQ Delta Rev Chg LTM | -10.0% |
| Op Mgn LTM | -1,181.1% |
| Op Mgn 3Y Avg | -578.6% |
| QoQ Delta Op Mgn LTM | -59.4% |
| CFO/Rev LTM | -1,145.7% |
| CFO/Rev 3Y Avg | -455.8% |
| FCF/Rev LTM | -1,145.7% |
| FCF/Rev 3Y Avg | -455.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.0 |
| P/S | 12.1 |
| P/EBIT | -0.8 |
| P/E | -0.9 |
| P/CFO | -0.9 |
| Total Yield | -114.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -147.7% |
| D/E | 0.1 |
| Net D/E | -0.8 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.6% |
| 3M Rtn | -28.5% |
| 6M Rtn | -16.3% |
| 12M Rtn | -54.7% |
| 3Y Rtn | -95.0% |
| 1M Excs Rtn | -2.1% |
| 3M Excs Rtn | -29.5% |
| 6M Excs Rtn | -28.3% |
| 12M Excs Rtn | -69.5% |
| 3Y Excs Rtn | -167.6% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| ANDA208508 | TICAGRELOR | ticagrelor | tablet | 10282025 | -30.4% | -33.7% | -33.7% | -33.7% | -33.7% |
| ANDA213348 | RIVAROXABAN | rivaroxaban | tablet | 5142025 | 7.9% | 27.3% | -12.2% | -12.2% | -12.2% |
| ANDA213037 | ARIPIPRAZOLE | aripiprazole | tablet | 10022023 | -14.2% | -66.4% | -99.5% | -99.8% | -99.8% |
| ANDA214004 | METOPROLOL SUCCINATE | metoprolol succinate | tablet, extended release | 9262022 | -20.3% | -6.1% | -62.6% | -99.8% | -99.9% |
| ANDA214748 | BRIVARACETAM | brivaracetam | tablet | 6092022 | -21.1% | -44.8% | -57.9% | -99.6% | -100.0% |
| ANDA213594 | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | for suspension | 1052022 | 419,233.3% | 76,566.7% | 47,966.6% | 17,500.0% | -59.3% |
| ANDA208335 | LINAGLIPTIN | linagliptin | tablet | 8312021 | 0.0% | 115,900.0% | 73,233.3% | 28,493.3% | -59.3% |
| ANDA208336 | LINAGLIPTIN AND METFORMIN HYDROCHLORIDE | linagliptin | tablet | 8302021 | 0.0% | 106,566.7% | 73,233.3% | 29,066.7% | -59.3% |
| ANDA212328 | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | capsule, delayed rel pellets | 2112021 | 0.0% | 0.0% | 0.0% | 66,560.0% | -59.3% |
| ANDA213496 | TADALAFIL | tadalafil | tablet | 11232020 | 0.0% | 0.0% | 0.0% | 57,486.7% | -59.3% |
| ... | |||||||||
Price Behavior
Price Behavior
| Market Price | $1.22 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/12/2010 | |
| Distance from 52W High | -57.2% | |
| 50 Days | 200 Days | |
| DMA Price | $1.34 | $1.48 |
| DMA Trend | down | down |
| Distance from DMA | -8.9% | -17.5% |
| 3M | 1YR | |
| Volatility | 46.3% | 67.2% |
| Downside Capture | 245.43 | 204.55 |
| Upside Capture | 7.80 | 86.36 |
| Correlation (SPY) | 30.0% | 39.4% |
SBFM Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.00 | 1.10 | 1.24 | 0.95 | 1.38 | 1.37 |
| Up Beta | 3.88 | 2.06 | 1.01 | 0.34 | 0.56 | 0.60 |
| Down Beta | -0.19 | 0.73 | 1.15 | 2.05 | 2.28 | 2.36 |
| Up Capture | 98% | 26% | 7% | 31% | 96% | -2% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 14 | 20 | 48 | 102 | 301 |
| Down Capture | 158% | 199% | 221% | 101% | 147% | 113% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 21 | 31 | 58 | 126 | 417 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SBFM | |
|---|---|---|---|---|
| SBFM | -52.6% | 66.6% | -0.85 | - |
| Sector ETF (XLV) | 7.7% | 17.2% | 0.27 | 25.8% |
| Equity (SPY) | 16.1% | 19.2% | 0.65 | 39.2% |
| Gold (GLD) | 76.5% | 23.4% | 2.38 | -0.2% |
| Commodities (DBC) | 11.1% | 15.9% | 0.48 | 19.1% |
| Real Estate (VNQ) | 5.3% | 16.5% | 0.14 | 30.5% |
| Bitcoin (BTCUSD) | -18.9% | 39.9% | -0.43 | 18.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SBFM | |
|---|---|---|---|---|
| SBFM | -80.5% | 172.7% | -0.52 | - |
| Sector ETF (XLV) | 7.1% | 14.5% | 0.31 | 10.9% |
| Equity (SPY) | 14.0% | 17.1% | 0.65 | 11.9% |
| Gold (GLD) | 20.8% | 16.5% | 1.03 | -4.0% |
| Commodities (DBC) | 12.2% | 18.8% | 0.53 | -9.4% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 5.9% |
| Bitcoin (BTCUSD) | 21.1% | 57.5% | 0.56 | 4.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SBFM | |
|---|---|---|---|---|
| SBFM | -63.7% | 211.6% | -0.15 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.52 | 3.2% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 4.2% |
| Gold (GLD) | 15.6% | 15.3% | 0.85 | -2.2% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | -5.7% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 2.9% |
| Bitcoin (BTCUSD) | 71.5% | 66.4% | 1.11 | -0.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/2/2025 | 8.2% | -31.2% | -32.2% |
| 11/7/2024 | -1.1% | -5.5% | 9.6% |
| 8/19/2024 | -3.6% | -5.2% | -3.2% |
| 4/1/2024 | 76.0% | 68.6% | -85.8% |
| 11/13/2023 | -12.1% | -8.3% | -10.0% |
| 8/11/2023 | 0.0% | -9.2% | -26.5% |
| 5/11/2023 | -18.8% | -29.7% | -37.5% |
| SUMMARY STATS | |||
| # Positive | 3 | 1 | 1 |
| # Negative | 4 | 6 | 6 |
| Median Positive | 8.2% | 68.6% | 9.6% |
| Median Negative | -7.8% | -8.8% | -29.3% |
| Max Positive | 76.0% | 68.6% | 9.6% |
| Max Negative | -18.8% | -31.2% | -85.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 04/01/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 08/16/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-Q |
| 12/31/2023 | 03/28/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 04/04/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 03/21/2022 | 10-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.